NCT04055649View on ClinicalTrials.gov

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

May 28, 2026

Study Completion Date

May 28, 2027

Conditions
Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma
Interventions
DRUG

Akt/ERK Inhibitor ONC201

Given orally (PO)

DRUG

Paclitaxel

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

48532

RECRUITING

Karmanos Cancer Institute at McLaren Flint, Flint

All Listed Sponsors
lead

Ira Winer

OTHER